Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 77

Sort by

Sort Order Select

Journal Articles

A New Antibody-Drug Conjugate Composed of an Anti-HLA-DR IgG4 Antibody, IMMU-114, and SN-38, Is Active in Experimental Acute Myelocytic Leukemia (AML), Acute Lymphocytic Leukemia (ALL), and Multiple Myeloma (MM)

David M Goldenberg, ScD, MD, Robert M Sharkey, Ph.D., Serengulam V Govindan, PhD, Maria Zalath, BA, Ali Mostafa, BS, Thomas M Cardillo, Ph.D.

Blood (2016) 128 (22): 3958.

https://doi.org/10.1182/blood.V128.22.3958.3958

Published: 2016

Journal Articles

Hyper-CVAD Plus Epratuzumab As Salvage Regimen for Younger Relapsed/Refractory CD22+ B Acute Lymphoblastic Leukemia (ALL) Patients: Results of the Phase 2 Prospective Cheprall Study

Blood (2016) 128 (22): 4018.

https://doi.org/10.1182/blood.V128.22.4018.4018

Published: 2016

Journal Articles

Subcutaneous Injections of IMMU-114 (Anti-HLA-DR IgG4 Monoclonal Antibody): Initial Results of a Phase I First-in-Man Study in Hematologic Malignancies

Deborah M. Stephens, DO, Alexander N Starodub, MD PhD, John C Byrd, MD, Heather Horne, William A Wegener, MD PhD, David M Goldenberg, ScD, MD, Beth A Christian, MD

Blood (2015) 126 (23): 2740.

https://doi.org/10.1182/blood.V126.23.2740.2740

Published: 2015

Journal Articles

Chemoimmunotherapy Combining Vincristine, Dexamethasone and Epratuzumab (hLL2) As Salvage Regimen for Older Relapsed/Refractory, CD22 + B-Acute Lymphoblastic Leukemia (B-ALL) Patients: Results of the French Non-Intensive Phase 2 Prospective Cheprall Study

Patrice Chevallier, Françoise Huguet, Emmanuel Raffoux, MD, Anne Etienne, MD, Thibaut Leguay, MD, Françoise Isnard, MD, Nelly Robillard, Thierry Guillaume, MD, Jacques Delaunay, MD, Pierre Peterlin, MD, Aude Charbonnier, MD, Arnaud Pigneux, MD PhD, Claire Le Houerou, David M Goldenberg, ScD, MD, William A Wegener, MD PhD, Hervé Dombret, MD PhD

Blood (2014) 124 (21): 3710.

https://doi.org/10.1182/blood.V124.21.3710.3710

Published: 2014

Journal Articles

A Phase I Study of Milatuzumab for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients with Hematologic Malignancies

Bradley M. Haverkos, MD MPH, Katie Cortright, BS, Leslie A. Andritsos, MD, William Blum, MD, Rebecca B. Klisovic, MD, Sumithira Vasu, MBBS, David M Goldenberg, ScD, MD, William A Wegener, MD PhD, Steven M. Devine, MD, Samantha M. Jaglowski, MD MPH

Blood (2014) 124 (21): 1168.

https://doi.org/10.1182/blood.V124.21.1168.1168

Published: 2014

Journal Articles

Phase 1 Dose-Escalation Study of 90 yttrium-Labeled Anti-CD22 Epratuzumab Tetraxetan in Adults with Refractory/Relapsed CD22 + B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Blood (2014) 124 (21): 3708.

https://doi.org/10.1182/blood.V124.21.3708.3708

Published: 2014

Journal Articles

BCR-ABL1 Molecular Remission After 90 y-Epratuzumab Tetraxetan Radioimmunotherapy In CD22 + Ph + B-ALL: A Potential New Treatment Paradigm

Patrice Chevallier, MD, PhD, Caroline bodet-Milin, MD, Nelly Robillard, Thomas Eugene, MD, Audrey Ménard, Claire Le Houerou, Thierry Guillaume, MD, Jacques Delaunay, MD, Martine Escoffre-Barbe, William A Wegener, MD, PhD, David M Goldenberg, ScD, MD, Françoise kraeber-Bodere, MD

Blood (2013) 122 (21): 3910.

https://doi.org/10.1182/blood.V122.21.3910.3910

Published: 2013

Journal Articles

Immunornase Therapy Of Lymphoma With Novel CD22-Targeting Quadruple Ranpirnase

Donglin Liu, Ph.D., Thomas M Cardillo, Ph.D, David M Goldenberg, ScD, MD, Chien-Hsing Chang, Ph.D

Blood (2013) 122 (21): 3075.

https://doi.org/10.1182/blood.V122.21.3075.3075

Published: 2013

Journal Articles

A New Platform For Trivalent Bispecific Antibodies Used For T-Cell Redirected Killing Of B-Cell Malignancies

Diane L Rossi, M.S., Edmund A Rossi, Ph.D, David M Goldenberg, ScD, MD, Chien-Hsing Chang, Ph.D

Blood (2013) 122 (21): 3078.

https://doi.org/10.1182/blood.V122.21.3078.3078

Published: 2013

Journal Articles

Comparison Of Two Dosing Schedules For Subcutaneous Injections Of Low-Dose Anti-CD20 Veltuzumab In Relapsed Immune Thrombocytopenia: Final Results Of a Phase I Study

Howard Liebman, MD, James B Bussel, MD, Mansoor N Saleh, MD, Heather Horne, William A Wegener, MD, PhD, David M Goldenberg, ScD, MD

Blood (2013) 122 (21): 1080.

https://doi.org/10.1182/blood.V122.21.1080.1080

Published: 2013

Journal Articles

Bispecific Hexavalant Antibodies With Enhanced Trogocytosis For Treatment Of Lupus

Edmund A Rossi, Ph.D, Rosana Michel, M.S., Chien-Hsing Chang, Ph.D, David M Goldenberg, ScD, MD

Blood (2013) 122 (21): 2282.

https://doi.org/10.1182/blood.V122.21.2282.2282

Published: 2013

Journal Articles

Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab

Edmund A. Rossi, David M. Goldenberg, Rosana Michel, Diane L. Rossi, Daniel J. Wallace, Chien-Hsing Chang

Blood (2013) 122 (17): 3020–3029.

https://doi.org/10.1182/blood-2012-12-473744

Published: 2013

Includes: Supplemental data

Journal Articles

A New Class of Hexavalent Bispecific Antibodies and Immunocytokines with Enhanced Pharmacokinetics and Improved Efficacy in Vivo .

Edmund A Rossi, Ph.D, Thomas M Cardillo, Ph.D, David M Goldenberg, ScD, MD, Chien-Hsing Chang, Ph.D

Blood (2012) 120 (21): 2451.

https://doi.org/10.1182/blood.V120.21.2451.2451

Published: 2012

Journal Articles

CD22-Targeting Epratuzumab Down-Regulates Multiple BCR Regulators On the Surface of Normal, Lupus, and Malignant B Cells

Edmund A Rossi, Ph.D, Rosana Michel, M.S., Daniel J Wallace, MD, Chien-Hsing Chang, Ph.D, David M Goldenberg, ScD, MD

Blood (2012) 120 (21): 1357.

https://doi.org/10.1182/blood.V120.21.1357.1357

Published: 2012

Journal Articles

Monotherapy with Subcutaneous (SC) Injections of Low Doses of Humanized Anti-CD20 Veltuzumab Is Active in Chronic Lymphocytic Leukemia (CLL)

Matt Kalaycio, MD, O George Negrea, MD, Rebecca Elstrom, MD, Charles Farber, MD, PhD, Heather Horne, William A Wegener, MD, PhD, David M Goldenberg, ScD, MD

Blood (2012) 120 (21): 192.

https://doi.org/10.1182/blood.V120.21.192.192

Published: 2012

Journal Articles

Phase I/II Study of Monotherapy with Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab in Relapsed Immune Thrombocytopenia

Howard A. Liebman, MA, MD, Mansoor N Saleh, MD, James B. Bussel, MD, O George Negrea, MD, Heather Horne, William Wegener, MD, PhD, David M Goldenberg, ScD, MD

Blood (2012) 120 (21): 622.

https://doi.org/10.1182/blood.V120.21.622.622

Published: 2012

Journal Articles

Combination Therapy Targeting Two Different Antigens with Anti-CD22 Radioimmunotherapy and Anti-CD20 Immunotherapy in Non-Hodgkin Lymphoma (NHL): Phase I Results

Michael B Tomblyn, MD, MS, Thomas E. Witzig, MD, Andrew L Himelstein, MD, Rebecca Elstrom, MD, Ebenezer A Kio, MD, Robert M Sharkey, PhD, Jonathan Rojo, MD, William Wegener, MD, PhD, David M Goldenberg, ScD, MD

Blood (2012) 120 (21): 3680.

https://doi.org/10.1182/blood.V120.21.3680.3680

Published: 2012

Journal Articles

Prevention of Acute Graft-Versus-Host Disease in Human/Mouse Xenogeneic SCID Mouse Model by Humanized Anti-CD74 Monoclonal Antibody, Milatuzumab

Xiaochuan Chen, Ph.D, Chien-Hsing Chang, Ph.D, Rhona Stein, Ph.D, Thomas M Cardillo, Ph.D, David V. Gold, Ph.D., David M Goldenberg, ScD, MD

Blood (2012) 120 (21): 4105.

https://doi.org/10.1182/blood.V120.21.4105.4105

Published: 2012

Journal Articles

A Novel T-Cell Redirecting Anti-CD19-F(ab) 2 /CD3scFv Bispecific Antibody Exhibits Potent Lymphoma Cytotoxicity.

Diane L Rossi, M.S., Edmund A Rossi, Ph.D, Thomas M Cardillo, Ph.D, David M Goldenberg, ScD, MD, Chien-Hsing Chang, Ph.D

Blood (2012) 120 (21): 2762.

https://doi.org/10.1182/blood.V120.21.2762.2762

Published: 2012

Journal Articles

Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90 y-Epratuzumab Tetraxetan Following R-CHOP in Elderly DLBCL Patients: A Lysa Phase II Prospective Trial

Blood (2012) 120 (21): 906.

https://doi.org/10.1182/blood.V120.21.906.906

Published: 2012

NARROW

A New Antibody-Drug Conjugate Composed of an Anti-HLA-DR IgG4 Antibody, IMMU-114, and SN-38, Is Active in Experimental Acute Myelocytic Leukemia (AML), Acute Lymphocytic Leukemia (ALL), and Multiple Myeloma (MM)

Hyper-CVAD Plus Epratuzumab As Salvage Regimen for Younger Relapsed/Refractory CD22+ B Acute Lymphoblastic Leukemia (ALL) Patients: Results of the Phase 2 Prospective Cheprall Study

Subcutaneous Injections of IMMU-114 (Anti-HLA-DR IgG4 Monoclonal Antibody): Initial Results of a Phase I First-in-Man Study in Hematologic Malignancies

Chemoimmunotherapy Combining Vincristine, Dexamethasone and Epratuzumab (hLL2) As Salvage Regimen for Older Relapsed/Refractory, CD22 + B-Acute Lymphoblastic Leukemia (B-ALL) Patients: Results of the French Non-Intensive Phase 2 Prospective Cheprall Study

A Phase I Study of Milatuzumab for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients with Hematologic Malignancies

Phase 1 Dose-Escalation Study of 90 yttrium-Labeled Anti-CD22 Epratuzumab Tetraxetan in Adults with Refractory/Relapsed CD22 + B-Cell Acute Lymphoblastic Leukemia (B-ALL)

BCR-ABL1 Molecular Remission After 90 y-Epratuzumab Tetraxetan Radioimmunotherapy In CD22 + Ph + B-ALL: A Potential New Treatment Paradigm

Immunornase Therapy Of Lymphoma With Novel CD22-Targeting Quadruple Ranpirnase

A New Platform For Trivalent Bispecific Antibodies Used For T-Cell Redirected Killing Of B-Cell Malignancies

Comparison Of Two Dosing Schedules For Subcutaneous Injections Of Low-Dose Anti-CD20 Veltuzumab In Relapsed Immune Thrombocytopenia: Final Results Of a Phase I Study

Bispecific Hexavalant Antibodies With Enhanced Trogocytosis For Treatment Of Lupus

Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab

A New Class of Hexavalent Bispecific Antibodies and Immunocytokines with Enhanced Pharmacokinetics and Improved Efficacy in Vivo .

CD22-Targeting Epratuzumab Down-Regulates Multiple BCR Regulators On the Surface of Normal, Lupus, and Malignant B Cells

Monotherapy with Subcutaneous (SC) Injections of Low Doses of Humanized Anti-CD20 Veltuzumab Is Active in Chronic Lymphocytic Leukemia (CLL)

Phase I/II Study of Monotherapy with Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab in Relapsed Immune Thrombocytopenia

Combination Therapy Targeting Two Different Antigens with Anti-CD22 Radioimmunotherapy and Anti-CD20 Immunotherapy in Non-Hodgkin Lymphoma (NHL): Phase I Results

Prevention of Acute Graft-Versus-Host Disease in Human/Mouse Xenogeneic SCID Mouse Model by Humanized Anti-CD74 Monoclonal Antibody, Milatuzumab

A Novel T-Cell Redirecting Anti-CD19-F(ab) 2 /CD3scFv Bispecific Antibody Exhibits Potent Lymphoma Cytotoxicity.

Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90 y-Epratuzumab Tetraxetan Following R-CHOP in Elderly DLBCL Patients: A Lysa Phase II Prospective Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only